Cephalon continuously expands our therapeutic focus, exploring new solutions and enhancing our knowledge of how our today’s products can improve patient health in new ways. Clinical trial enrollment is an integral part of that process.

For more information about Cephalon clinical trials in progress or how to enroll in a study, please consult the following list, which provides links to relevant pages on the National Institute of Health’s www.clinicaltrials.gov website. Click on the title of the study in which you are interested for information such as recruitment status, criteria for participation and contact information.

Cephalon is recruiting patients for clinical trials in the following areas:

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Comorbid Major Depressive Disorder or Dysthymic Disorder

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Study of CEP-701 in Patients With Acute Myeloid Leukemia (AML)

Open-Label Study of Oral CEP-701 (lestaurtinib) in Patients with Polycythemia Vera or Essential Thrombocytosis

Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide, Compared With Low-Dose Cytarabine Alone, for the Treatment of Elderly Patients With Acute Myeloid Leukemia (AML)

Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain